Alturas Analytics, Inc.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.

Custom Biologics provide exceptional, high quality, customized assays to measure the functional properties of cellular and biotherapeutic drug candidates. We are a Health Canada audited, GMP-compliant, global service provider for functional testing of biotherapeutics, biosimilars and antibody drug conjugates.

For over 14 years our scientists have been designing and validating sophisticated bioanalytical assays, to characterize and measure the therapeutic potential of large and small molecule biotherapeutics.

Our work supports regulatory drug submission applications from biopharmaceutical companies throughout North America, Europe and Asia.

Great Science - It's at the heart of everything we do!

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases.

As part of our ImQuest SUCCESS platform, we provide expert preclinical research services, including compound screening to define compound efficacy and drug target validation analysis to define the mechanism of action and toxicity of pharmaceutical products. We specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines for infectious disease and cancer drug development programs.

Our preclinical contract research services are comprised of interrelated efficacy-defining components for infectious disease (including microbiology and virology), cancer and women's health with parallel evaluations of in vitro and ex vivo toxicity and the pharmaceutical properties and chemical structure of preclinical candidates to efficiently validate you drug target.

We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. Our team has decades of experience in the field of virology, microbiology and oncology. As such, we understand that each product and each client is unique and we strive to provide effective solutions.

Plexera manufactures high throughput Surface Plasmon Resonance Imaging (SPRi) instruments for the life sciences market. Users of the Plexera platform are provided with tools, content, and application methods that simplify, accelerate, and lower the cost of drug discovery and development.

Plexera's PlexArray® HT is a high-throughput, label-free biomolecular interaction detection system based on Surface Plasmon Resonance imaging (SPRi) technology. The PlexArray® HT is a fully integrated, easy to use platform for analyzing 10’s, 100’s, or 1000’s of biomolecular interactions in a single reaction.

Plexera offers customized contract research services for a wide range of applications includes small molecule drug discovery, protein characterization, analysis of target selectivity and specificity, antibody screening and selection, and biomarker discovery.

RiboWiz Scientific is a digital biotechnology company integrating both A.I. software and life science. RiboWiz offers customized service and cloud-based subscription licensing to accurately predict and maximize recombinant protein production for life science companies using proprietary RiboScan™ software platform.

Creating high-value recombinant proteins, e.g. biologics, enzymes, vaccines, antibodies, and pesticides, is important to life science companies across a broad range of industrial applications. For example, proteins can be over-expressed for use in basic research, used as insecticides, or used as targets for small molecule drugs or antibodies for the treatments of AIDS, diabetes, cancer and other diseases.

Many R&D projects are stymied by conventional protein expression methods that require multiple trial-and-error laboratory testing to produce proteins at the desired level. RiboScan™ provides more of the desired protein candidates with fewer folding errors and protein aggregations by simulating and modulating ribosomal speed and accuracy during protein synthesis.

Unlike current alternatives that require synthesis and laboratory testing of hundreds of genes construct, RiboScan™ accurately predicts protein expression levels and designs an optimized gene construct with minimal subsequent laboratory testing. This significantly accelerates clients’ R&D projects, reduces costs, expedites innovations, and enhances protein quality to make clients more competitive in bringing multiple novel compounds to market faster.

RiboWiz’s mission is to help clients successfully produce high-value, difficult-to-make recombinant proteins faster for new treatments of diseases and also for the advancement of medicine and biotechnology.